Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1967 5
1968 2
1970 1
1971 1
1972 1
1973 1
1974 1
1976 1
1978 1
1980 1
1982 1
1983 4
1984 2
1985 2
1987 3
1991 1
1994 1
1997 1
1999 2
2003 1
2004 3
2005 1
2006 2
2007 3
2008 3
2009 10
2010 8
2011 12
2012 8
2013 6
2014 9
2015 11
2016 11
2017 15
2018 13
2019 18
2020 22
2021 24
2022 23
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Results by year

Filters applied: . Clear all
Page 1
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: bradbury p. J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36841541 Clinical Trial.
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. Anagnostou V, et al. Among authors: bradbury pa. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9. Nat Med. 2023. PMID: 37814061 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Among authors: bradbury p. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
Automating Access to Real-World Evidence.
Gauthier MP, Law JH, Le LW, Li JJN, Zahir S, Nirmalakumar S, Sung M, Pettengell C, Aviv S, Chu R, Sacher A, Liu G, Bradbury P, Shepherd FA, Leighl NB. Gauthier MP, et al. Among authors: bradbury p. JTO Clin Res Rep. 2022 May 17;3(6):100340. doi: 10.1016/j.jtocrr.2022.100340. eCollection 2022 Jun. JTO Clin Res Rep. 2022. PMID: 35719866 Free PMC article.
iRECIST and atypical patterns of response to immuno-oncology drugs.
Ramon-Patino JL, Schmid S, Lau S, Seymour L, Gaudreau PO, Li JJN, Bradbury PA, Calvo E. Ramon-Patino JL, et al. Among authors: bradbury pa. J Immunother Cancer. 2022 Jun;10(6):e004849. doi: 10.1136/jitc-2022-004849. J Immunother Cancer. 2022. PMID: 35715004 Free PMC article. Review.
Occupy tissue: the movement in cancer metastasis.
Bradbury P, Fabry B, O'Neill GM. Bradbury P, et al. Cell Adh Migr. 2012 Sep-Oct;6(5):424-32. doi: 10.4161/cam.21559. Epub 2012 Sep 1. Cell Adh Migr. 2012. PMID: 23076050 Free PMC article. Review.
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. O'Kane GM, et al. Among authors: bradbury pa. Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Lung Cancer. 2017. PMID: 28577943 Review.
Immunotherapy for lung cancer.
Bradbury PA, Shepherd FA. Bradbury PA, et al. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S164-70. doi: 10.1097/JTO.0b013e318174e9a7. J Thorac Oncol. 2008. PMID: 18520304 Free article. Review.
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM, Rabindranath M, Weiss J, Li JJN, Fung AS, Mullen D, Alshamlan N, Ruff HM, Tong LCB, Pal P, Cabanero MR, Hsu YR, Sacher AG, Shepherd FA, Liu G, Bradbury PA, Yasufuku K, Czarnecka-Kujawa K, Mi Ko H, Tsao MS, Leighl NB, Schwock J. Lau SCM, et al. Among authors: bradbury pa. Lung Cancer. 2022 Sep;171:42-46. doi: 10.1016/j.lungcan.2022.07.018. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35907387 Review.
224 results